GlassScriptPhysician profile
Stephen Yuliang Chen
NPI 1114060514
$8,853.63
in general payments reported to CMS, 2019-2025
21 companies · $1,465 in 2025
The $1,465 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $277 · 2021: $402 · 2022: $2,376 · 2023: $1,424 · 2024: $2,581 · 2025: $1,465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,721 · Travel and Lodging: $2,319 · Consulting Fee: $430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,721.08 |
| Travel and Lodging | $2,319.04 |
| Consulting Fee | $430.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,553.84 | 2019-2025 | Triclip, Amplatzer Amulet, Amplatzer |
| Edwards Lifesciences Corporation | $2,460.41 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Philips North America LLC | $975.31 | 2023-2024 | (9525) Intracardiac Und, (9520) Igt Devices Undivided |
| Amgen INC. | $600.07 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $520.99 | 2022-2025 | Watchman Access System |
| Shockwave Medical, INC | $323.27 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novartis Pharmaceuticals Corporation | $268.18 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $245.23 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $166.27 | 2019-2023 | Farxiga |
| Abiomed | $157.30 | 2022-2025 | |
| Biotronik INC. | $114.61 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $102.45 | 2019-2025 | Dupixent |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $77.23 | 2019-2024 | Lifevest |
| Inari Medical, INC. | $70.10 | 2021 | |
| Medtronic, INC. | $51.78 | 2023-2024 | Corevalve Evolut R, Linq II |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $51.15 | 2023-2025 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $32.15 | 2025 | Amvuttra |
| Esperion Therapeutics, INC. | $26.06 | 2023 | Nexletol |
| Novo Nordisk INC | $20.90 | 2025 | Wegovy |
| Conmed Corporation | $20.31 | 2025 | Airseal |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.